Edicotinib is a targeted therapy primarily used in oncology for treating non-small cell lung cancer (NSCLC), particularly in patients with EGFR gene mutations. It acts as an inhibitor of specific kinases, including EGFR, involved in the growth and proliferation of cancer cells. By blocking these kinases, Edicotinib helps inhibit cancer cell growth and slow disease progression. It may also be used for other EGFR-mutated cancers, such as colorectal cancer. Its use is typically guided by genetic testing to ensure suitability for patients with appropriate genetic profiles. Ongoing clinical trials are evaluating its efficacy and safety, both as monotherapy and in combination with other therapies, representing a promising approach in personalized medicine to precisely target cancer while minimizing side effects.